Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (422)	10/15/2017 1:15:22 PM
From: ghmm	1 Recommendation Recommended By scaram(o)uche Read Replies (1) \| Respond to of 684

Thanks for the background Jim! On the debt I was more wondering if there is a change of control provision requiring them to pay it before and/or they have an agreement to convert to shares of newco. GT companies have done quite well of late.. guess I went from thinking them cheap to some seemingly pricing in success of more than their lead program. I'm having trouble finding ones I think aren't pricing in any form of success even at the preclinical level big difference a couple months make! Looking at your list here from a couple months of ago DMTX buy out, 2 reverse mergers into GT companies even ADVM us up a bit.